Open Access policy
Articles submitted to Drug Target Insights (DTI) are published after having successfully completed their peer-review process. The publication of open access articles is covered by an Article Processing Charge (APC) paid by the author after acceptance. There are no submission fees, no fees for rejected articles and there is no additional cost for manuscript length, colour items or supplementary files, including videos. APC is waived for invited reviews and editorials.
All readers have unlimited access to the full text of all articles published in the journal, without subscription or other firewalls, with no embargo period. Open Access contents are therefore more effectively included in search engines and indexing databases, resulting in larger visibility and higher citation. Authors contributing to DTI agree to publish their articles under the Creative Commons Attribution Non-Commercial CC-BY-NC 4.0 (CC-BY-NC 4.0) license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. Re-use for commercial purposes is not permitted. Contact our permission office.
Manuscripts funded by the Wellcome Trust, RCUK, and other organizations with the same requirements, Open Access papers are published under the Creative Common Attribution 4.0 International (CC BY 4.0) which allows users to:
- copy and redistribute the material in any medium or format
- remix, transform, and build upon the material for any purpose, even commercially.
For additional information on our open access policy, please contact us.